Post

2) The graph below shows the main findings. Unfortunately, there wasn't a placebo control group only a group that received no drug, only usual care. The primary outcome was the Fatigue Assessment Scale (FAS, range: 10-50), with higher scores indicating worse fatigue.

3) The authors indicated that 3 points on the FAS can be seen as the minimally clinically important difference. For all three treatments, the benefit compared to no treatment was lower than 3 points, so they didn't produce a significant benefit.

How was the minimum useful difference calculated?

4) The negative result was clearest for the anticoagulant rivaroxaban (difference: –1·06 [95% confidence interval: –2·47 to 0·35]; p-value= 0·139). This finding questions whether blood clotting is a relevant factor in Long Covid patients.